MapLight Therapeutics, Inc. (MPLT) vs ARS Pharmaceuticals, Inc. (SPRY)
A side-by-side comparison of MapLight Therapeutics, Inc. and ARS Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MPLT
MapLight Therapeutics, Inc.
$9.72HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
SPRY
ARS Pharmaceuticals, Inc.
$4.29HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — MPLT vs SPRY
growth of $100 · dividends reinvested · last 1yMPLT -49.4% (-49.4%/yr)SPRY -55.1% (-55.1%/yr)MPLT compounded faster over this window
MPLT SPRY
MPLT vs SPRY: by the numbers
- •SPRY is the larger company ($426M vs $412M market cap).
- •Both run net losses; MPLT's is the smaller (0.00% vs -184.24% net margin).
Metrics side by side
Valuation
| Metric | MPLT | SPRY |
|---|---|---|
| P/S ratio | N/A | 3.64 |
| P/B ratio | 1.18 | 34.06 |
Profitability
| Metric | MPLT | SPRY |
|---|---|---|
| Gross margin | 0.00% | 73.89% |
| Operating margin | 0.00% | -212.92% |
| Net margin | 0.00% | -184.24% |
| ROE | -65.99% | -1721.80% |
| ROIC | -69.35% | -114.65% |
Growth (annualized)
| Metric | MPLT | SPRY |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 36.43% |
| Total return CAGR (5Y) | N/A | -16.35% |
Go deeper
Dig into the metrics
MapLight Therapeutics ROEARS Pharmaceuticals ROEMapLight Therapeutics operating marginARS Pharmaceuticals operating marginMapLight Therapeutics revenue growthARS Pharmaceuticals revenue growthMapLight Therapeutics free cash flowARS Pharmaceuticals free cash flow
MapLight Therapeutics & ARS Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.